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Abstract  
Therapeutic tolerance embraces the concept of ‘switching off’ immunopathology by 
specifically targeting elements of the immune system.  It has been achievable in 
preclinical models of transplantation and autoimmunity for more than two decades, 
but previous attempts to translate to the clinic have been unsuccessful.  However, an 
improved understanding of tolerance mechanisms, along with novel therapeutic 
agents and strategies, are starting to bear fruit in a number of disease areas.  True 
tolerance is achievable in transplantation settings, and long-term remissions can be 
induced in various autoimmune and atopic conditions.  Equivalent outcomes should 
be achievable in inflammatory arthritis although this may require an improved 
understanding of the immune dysregulation that is intrinsic to RA, and better 
definition of RA autoantigens.  Biomarkers of tolerance induction would rapidly 
advance the field in all therapeutic areas.  This chapter summarises the advances made 
in other therapeutic areas, and the lessons learned, that we can now apply to RA. 
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Introduction 
Current treatment paradigms for rheumatoid arthritis emphasise the need to 
treat inflammation aggressively to prevent joint damage and co-morbidities. Disease 
remission is the goal of therapy and can now be achieved in a proportion of patients, 
particularly in early disease. The question then arises as to whether therapy can be 
withdrawn or tapered but, certainly in established RA, treatment cessation leads to 
disease flare more often than if therapy is continued [1]. In essence the disease has 
been suppressed by therapy and re-emerges upon drug withdrawal. In contrast, 
immune tolerance is the natural state whereby the organism does not mount an 
immune response against self, whilst maintaining the ability to react to ‘foreign’ 
substances and tissues. By definition this process has broken down in autoimmune 
disease and the focus of this chapter is to ask whether it can be re-established by 
appropriate targeting of the immune system (therapeutic tolerance induction). 
The first clear evidence that immune tolerance could be induced by a 
therapeutic intervention dates back to the 1980s. Several groups demonstrated that 
short courses of monoclonal antibody (mAb) therapy, generally targetted at CD4 ± 
CD8 on T-cells, could allow the transplantation of foreign tissue grafts or switch off 
established autoimmunity [2]. In both cases a brief intervention resulted in life-long 
tolerance, with no evidence of immune deficiency. Subsequently, equally dramatic 
results were obtained using other more specific interventions such as antigenic 
peptide administration (via a number of alternative routes) or by mucosal 
administration of autoantigen. The important concept that evolved from this work was 
that the immune system was ‘plastic’ and, to an extent, immune memory could be 
controlled and/or replaced. Furthermore, therapeutic tolerance was shown to be an 
active process, involving, inter alia, regulatory T-cell induction [3]. This underpinned 
phenomena such as infectious tolerance, linked suppression and epitope spreading, 
which ensured the robustness of tolerance induction [4]. 
 
Definitions and a brief historical perspective 
To discuss therapeutic tolerance in terms of autoimmunity, definitions are 
paramount. In transplantation the situation is clear: if a foreign organ is accepted in 
the absence of immunosuppression in an otherwise immunocompetent host, then 
tolerance has been achieved. This occurs infrequently but immunosuppression is 
sometimes stopped in a transplanted patient (usually due to severe side effects or co-
existent disease) and, in occasional cases, the graft is not rejected (Figure 1A). In 
autoimmunity the situation is more complex and we are left with ‘operational’ 
definitions of tolerance. In RA, tolerance should manifest as an immunocompetent 
patient, in remission, on no immunosuppressive or anti-inflammatory therapy. 
However remission itself is a complex concept, and does occur spontaneously, for 
example in palindromic RA (Figure 1B)[5]. Whether this represents attempts by the 
immune system to reinstate self tolerance is unclear and a major limitation is our lack 
of biomarkers for the tolerant state (see Transplantation section below). In RA, true 
therapeutic tolerance induction should provide a disease ‘cure’, although physicians 
and patients alike would be content with an intermittent therapy that controlled 
disease for prolonged intervals without affecting immune competence.  
 Models of therapeutic tolerance induction generally propose a central role for 
the T-cell:antigen presenting cell (APC) interaction. Disruption and modulation of 
this key interaction underpins most tolerogenic interventions. Early preclinical 
protocols used brief courses of T-cell depleting mAbs to induce tolerance to foreign 
tissue or to reverse autoimmunity [2]. Subsequently, non-depleting mAbs were shown 
to be even more effective and it was demonstrated that a broad range of T-cell surface 
antigens could be targeted for tolerance induction. Models suggested that therapy 
acted by ‘blindfolding’ the key cells, preventing effective interactions and allowing 
the immune system to return to its natural state of self tolerance [6].  
 However, initial trials in RA patients failed to reproduce these exciting 
preclinical data [7]. A range of targets including CD4, CD5, and CD7 were selected 
but clinical improvement was generally transient or absent. In contrast anti-CD52 
(CAMPATH-1H) resulted in deep depletion of several lymphocyte subsets, and was 
associated with significant improvement in open label trials [8, 9]. However therapy 
was associated with first-dose reactions, and immune reconstitution was very slow. 
This led to concerns over long-term immune competence, although this has not 
proven to be a problem in the longer term [10, 11]. A flurry of anti-CD4 trials failed 
to demonstrate consistent benefit and the advent of anti-cytokine therapy slowed 
development in this area. Recently CTLA4-Ig (abatacept) has shown that T-cells can 
be targeted in a clinically effective manner. Abatacept blocks costimulation, thereby 
interrupting the second signal required for full T-cell activation. Historically, signal 2 
blockade was a highly effective means to induce tolerance in T-cells [12]. However 
abatacept is administered monthly, without longer breaks in therapy, preventing 
conclusions being drawn regarding its tolerogenic potential. Nonetheless, long-term 
observational studies of abatacept administration hint at enhanced efficacy with time, 
perhaps suggesting a gradual turning off of disease [13].  
 
Lessons from transplantation and other diseases 
It is almost 20 years since initial attempts to induce tolerance in RA patients. This 
work continues but, in parallel, strategies have been studied in a range of other 
immunopathologies, ranging from transplantation to allergy. The remainder of this 
chapter will study these examples and extract lessons that might be applied to RA 
 
1. Transplantation 
Transplantation models were some of the first to demonstrate true therapeutic 
tolerance. Even animals that were actively rejecting skin could be tolerised, rejection 
being converted to tolerance, perhaps one of the most dramatic examples of immune 
plasticity [14]. Despite the success of modern immunosuppressive regimes chronic 
rejection, drug toxicity and opportunistic infections create the need for improved 
methods to combat alloreactivity. Two major strategies have been employed. In the 
first, lymphocyte depletion around the time of transplantation mimics, to an extent, 
successful murine tolerance protocols. In this way drugs such as alemtuzumab or anti-
thymocyte globulin (ATG) have allowed the use of very significantly reduced post-
transplant immunosuppression [15]. Calne has termed this ‘prope (near) tolerance’, 
but acute and chronic rejection still occurs in some cases [16]. Furthermore, 
homeostatic proliferation may expand memory T-cell clones capable of rejection (see 
Safety Lessons section below).  
These observations suggest that lymphocyte deletion alone, at least to the sub-ablative 
levels achievable with mAb therapy, is unlikely to generate robust clinical tolerance. 
Presumably residual auto- or allo-reactive clones remain and these must be regulated 
in some way for true therapeutic tolerance induction. Several groups are therefore 
studying non-myeloablative (or mini) haematopoietic transplantation for tolerance 
induction. In conventional haematopoietic transplants, the recipient immune system is 
eradicated and replaced by the graft. In mini-transplants, conditioning is less stringent 
but still sufficient to allow engraftment of donor cells, resulting in a chimeric 
haematopoietic system, in which donor and host cells co-exist. The presence of donor 
cells, particularly APC, underpins the induction of both central and peripheral 
tolerance to donor antigens, and subsequent solid organ transplantation (from the 
same donor) without a requirement for long-term immunosuppression [17]. Although 
such protocols generally use living-related donors, graft versus host disease (GvHD) 
occurs in a proportion of patients and this may interrupt central tolerance 
mechanisms. Furthermore although the results to date are highly impressive, the 
robustness of the tolerant state remains uncertain. In particular, chimerism is lost in a 
significant proportion of patients. This is not associated with immediate breakdown of 
tolerance but could enhance the likelihood of later rejection episodes triggered by 
extrinsic insults such as infectious agents [16]. 
Transplantation tolerance is obvious when immunosuppressive drugs have been 
withdrawn but we cannot currently identify tolerant patients who remain on anti-
rejection medication. It is not appropriate to stop these drugs to ‘test’ tolerance, 
although the risk is less for some organs than for others. What are needed are 
biomarkers of tolerance that identify patients in whom therapy can be stopped. These 
could be present in serum, urine, or as a ‘molecular signature’. Recent attempts to 
define such biomarkers have produced interesting and mostly unexpected results. For 
example, B-cells, NK T-cells and γδ T-cells have featured as prominently as T-cells. 
Furthermore, potential biomarkers have differed according to the organ transplanted, 
and also with comorbidities [18]. Most remain to be validated but a tolerogenic 
biomarker would signal a massive advance for the identification of patients in whom 
immunosuppressive therapy may be safely discontinued. 
Tolerance biomarkers are even more essential in autoimmunity, where anecdotal 
reports have suggested long-term disease modulation following apparently 
unsuccessful trials of tolerogenic therapy [19]. Critical issues to consider here are that 
tolerance takes time to develop and that tolerogenic therapies may not have short-term 
anti-inflammatory effects [20]. Furthermore, because tolerance induction is an active 
process some anti-inflammatory and immunosuppressive drugs may counter tolerance 
induction. This has been demonstrated for ciclosporin, potentially cyclo-oxygenase-2 
inhibitors, and even corticosteroids [21]. Other drugs, such as rapamycin, may have 
pro- or anti-tolerogenic properties, depending on the precise setting [22, 23]. 
Therefore the period surrounding the administration of a potentially tolerogenic 
therapy in RA is a difficult one. Active inflammation may not be a sign that treatment 
is ineffective, yet the treatment of inflammation could be counter-productive, as could 
uncontrolled inflammation itself, which is designed to ‘drive’ immunity. Under these 
circumstances it is easy to understand how a potentially effective treatment might be 
abandoned prematurely. In contrast, biomarkers of early tolerance induction might 
signal that treatment is ‘working’, even whilst active synovitis persists, encouraging 
perseverance rather than abandonment of therapy. Such biomarkers would also help to 
identify the effects of immunosuppressive and anti-inflammatory drugs on tolerogenic 
mechanisms. In the future we may therefore monitor two types of biomarker: those 
that signal inflammation, such as the CRP, and those that signal tolerance; there will 
be circumstances under which the two readings provide distinct signals.   
In summary, transplantation has shown us that therapeutic tolerance is possible, albeit 
using sophisticated and powerful therapeutic regimes. It has also demonstrated the 
need for tolerance biomarkers to signal when immune suppression can be safely 
lifted. The need for such biomarkers is even stronger in inflammatory, autoimmune 
diseases. 
 
2. Diabetes  
During the last five years there has been encouraging progress in the application of 
tolerogenic therapies in type 1 diabetes. Most progress has been made with so-called 
non-activating, or non-mitogenic, anti-CD3 mAbs. OKT3, a murine anti-human CD3 
mAb has been used for many years in the transplant setting to treat steroid-refractory 
allograft rejection. Its potent immunosuppressive properties usually reverse rejection 
but at the expense of toxicity, in particular a first-dose cytokine storm. This can 
manifest in many ways, including adult respiratory distress syndrome and aseptic 
meningitis, and can prove fatal [24]. This has prevented its application in 
autoimmunity, where the cost-benefit balance is deemed unfavourable, and led to the 
development of so-called non-activating or non-mitogenic equivalents. The first-dose 
cytokine storm is the consequence of T-cell activation, which follows the cross-
linking of surface-bound anti-CD3 mAb by FcγR-bearing cells. Mutations in the mAb 
Fc region reduce or prevent cross-linking and hence significantly lessen first-dose 
reactions. Studies in preclinical models, such as diabetes-prone NOD mice, 
demonstrated a potent tolerogenic profile for F(ab’)2 fragment of anti-CD3 mAbs, 
which similarly cannot bind FcγR [25]. These reversed established diabetes and 
restored tolerance to islet antigens via a combination of effector T-cell silencing or 
death, and TGFβ-associated regulatory T-cell induction [26]. Two groups have used 
non-mitogenic anti-CD3 mAbs, teplizumab and otelixizumab, to treat patients with 
recent-onset type 1 diabetes. Patients with an appropriate family history and 
circulating autoantibodies were followed at regular intervals until the onset of 
impaired glucose tolerance. They were then treated with a brief course of anti-CD3 
therapy, in both cases non-mitogenic although via distinct Fc mutations [27, 28]. 
Recent follow-up of these patients has suggested a slowing of disease progression for 
at least 18 months and possibly up to 5 years [29, 30].  
The most important lesson to emerge from this work is the key importance of timing 
of therapy. In the European trial efficacy correlated with residual beta cell function at 
the time of therapy, and the patients with lowest C-peptide levels derived minimal 
benefit. Whilst not entirely surprising, treatment was within 6 weeks of disease onset, 
suggesting that treatment in the pre-clinical phase may have been even more effective. 
Rheumatologists recognise the importance of early RA treatment in terms of 
preventing joint damage but timing could be even more critical from the perspective 
of immune modulation because tolerance may breakdown several years before clinical 
disease [31]. The heritability of RA is less than for type 1 diabetes, rendering pre-
clinical disease harder to identify but a number of groups are starting to combine 
serology, genetics and demographic factors to potentially identify susceptible 
individuals.  
Teplizumab administration was associated with the appearance of IL-10 secreting 
CD4+ T-cells and FoxP3+ CD8+ regulatory T-cells, as well as an increased frequency 
of autoantigen-reactive CD8+ T-cells [32-34]. These were not used to predict 
response to therapy but could provide important pharmacodynamic clues. Pre-clinical 
data suggest that antigen-specific regulatory T-cells can be potently induced by a 
combination of anti-CD3 and nasal pro-insulin, thereby combining the non-specific 
tolerising effects of anti-CD3 with an antigen-specific signal[35]. 
In summary, T1D provides a useful clinical corollary to RA. The pathogenesis of both 
diseases appears similar and it is clear that T1D can be modulated by non-depleting 
anti-CD3 therapy. However, treating similarly early disease will provide a challenge 
for rheumatologists and the concept of identifying ‘pre-RA’ remains in its infancy. 
 
3. Safety lessons 
If tolerogenic therapies are to be used in early, or even preclinical, disease then safety 
becomes paramount. A significant issue with many biological therapies, particularly 
mAbs, is that toxicity may be difficult or impossible to predict from pre-clinical 
models [7]. Toxicity may be a direct consequence of the therapy itself, or secondary 
to resultant perturbations of the immune system. First-dose cytokine release reactions 
are a good example of the former, and the unpredictability of such reactions was 
exemplified by the TGN1412 ‘Northwick Park’ trial. A mAb that appeared very safe 
(and potently tolerogenic) in pre-clinical studies resulted in life-threatening side 
effects in four previously healthy subjects [36]. A potential explanation is the ability 
of human FcγRs to cross-link mAbs of human IgG4 isotype, thereby provoking T-cell 
activation. Even after the event, however, the precise mechanism proved very difficult 
to unravel [37]. The ‘phenotype’ of first dose reactions may also vary with disease. 
For example in multiple sclerosis patients treated with alemtuzumab, the first 
administration of drug was associated with a transient but worrying recurrence of 
previous neurological symptoms and signs, which correlated with circulating cytokine 
concentrations [38]. Not surprisingly, first-dose reactions are dose-related, as 
demonstrated by a recently aborted trial of teplizumab in T1D. In this study a change 
in drug packaging led to approximately 40% higher bioavailability, which appears to 
have been responsible for the enhanced toxicity [30]. As we start to think about 
biosimilars and ‘generic’ biologic drugs it becomes very important to recognise the 
many factors that can influence mAb PK and PD aside from simply the primary 
protein structure, such as the structure of the Fc-associated glycan [39]. Cytokine 
release reactions can also be provoked by extremely small mAb doses, as observed 
with a further anti-CD3 mAb, visilizumab. When used to treat refractory ulcerative 
colitis, doses as low as 10-15µg/kg were associated with first-dose reactions [40]. 
A good example of unpredicted secondary adverse events also emerges from 
alemtuzumab trials in MS. At present alemtuzumab looks to be one of the most potent 
therapies for MS. There may not be true tolerance induction but yearly pulses of this 
lymphocytotoxic therapy are highly effective at suppressing flares and curbing 
functional disability [41]. However, more than a quarter of patients subsequently 
develop secondary autoimmunity, most commonly of the thyroid gland [42]. Similar 
but less frequent events were also reported in patients receiving alemtuzumab for 
ANCA-positive vasculitis [43], Bechet’s disease [44], and following renal 
transplantation [45], and also in other lymphopenic settings, such as post bone 
marrow transplantation [46]. A recent study suggests these events are a complication 
of immune homeostasis, in which remaining, or newly developing, lymphocytes 
rapidly expand to fill the lymphopenic environment. Immune homeostasis depends on 
weak interactions with self-MHC, and so it is not surprising that autoimmunity can be 
a complication, particularly in individuals already predisposed to autoimmunity. 
Interestingly, in MS secondary autoimmunity is related to pre-treatment serum IL-21 
levels, in turn predicted by polymorphism in the IL-21 gene [47]. Some drugs, such as 
rapamycin, appear to influence the expanding homeostatic repertoire in favour of 
immune regulation [48-50]. This has yet to be linked to improved outcomes, at least 
in solid organ transplantation, but suggests ways in which such phenomena might be 
manipulated for benefit [51]. 
Immunosuppression is a potential consequence of any immunomodulatory 
therapy, and one that rheumatologists are very familiar with. Immunosuppression 
should only be temporary with tolerogenic therapies, however. In the European T1D 
trial, reactivation of EBV occurred in most patients in association with a CD8+ T-cell 
lymphocytosis that occurred a few weeks after therapy. EBV titres fell as the 
lymphocytosis resolved, suggesting that these CD8+ T-cells were targeting EBV 
reactivation in B-cells, demonstrating potent and specific immunocompetence within 
a few weeks of anti-CD3 administration [28]. 
In summary although targeted therapies are more specific than conventional 
immunosuppressive and immunomodulatory drugs, side effects will occur. Even with 
tolerogenic therapies infections should be anticipated in the short-term but  
unexpected and even paradoxical side effects may also be encountered. As with first-
dose reactions and secondary autoimmunity, a better understanding of these 
phenomena should result in better and targeted treatments. 
 
4. Atopy 
The therapies referred to thus far are antigen non-specific and, whilst these appear 
to be safe and to preserve immunocompetence, the ideal therapy is one that targets 
just the pathogenic clones of T-cells that are causing autoimmnity or transplant 
rejection. Atopy is a very common form of immunopathology, in which the inciting 
antigen is generally known. In atopic conditions it has proved possible to harness 
powerful immunomodulatory effects by using whole antigen or antigen-derived 
peptides.  
In allergic asthma, patients receiving by intradermal injection a combination of 
peptides derived from Fel d 1, the major cat allergen, demonstrated symptomatic 
improvement by a number of measures [52]. Reported studies are relatively small, 
however clinical responses generally correlate with surrogate response measures such 
as skin test reactivity and ex vivo measures of immune function. Thus, therapy is 
associated with reductions in TH1 and TH2-type responses and a shift towards an IL-
10 secreting regulatory population [53]. Recently, the latter cell population has been 
associated with the phenomenon of ‘linked suppression’ in patients responding to 
therapy [54]. Linked suppression and epitope spreading describe the situation where 
tolerance to administered peptides ‘spreads’ to involve additional peptide sequences 
present in the same protein or in other proteins present in the same location. The 
induction of such mechanisms will be critically important in terms of tolerogenic 
therapy for human autoimmunity, because there is a broad repertoire of autoantigens 
by the time disease is clinically apparent. These ex vivo data also serve as important 
biomarkers of efficacy, and add considerable credibility to the clinical data.  
Autoreactivity to heat shock proteins (HSP) has been demonstrated in a number of 
autoimmune conditions, including T1D, juvenile idiopathic arthritis (JIA) and RA. 
HSP peptide administration has provided some evidence of a biological effect in T1D, 
and ex vivo immunomodulatory effects have been suggested in rheumatic disease, but 
without clear clinical efficacy [55-57]. Because of the similarity between bacterial and 
human HSPs, such phenomena may implicate antigenic mimicry in autoimmune 
pathogenesis. However, the precise link between HSPs and autoimmunity remains 
unclear and the mode of action of HSP-based peptide therapies may differ from those 
in atopy. For example, some HSP peptides appear to exert a direct action via toll-like 
receptors [58]. 
Peptide-based therapy is assumed to operate by interfering with the T-cell 
receptor/MHC interaction. A related approach is to generate TCR ‘antagonists’, 
altered peptide ligands that differ from disease-associated peptides at key residues. In 
vitro and in pre-clinical models these appear to switch off autoreactive T-cells, 
perhaps by providing a partial signal, leading to tolerance induction. Trials of such a 
peptide in MS led to disease flares, however, apparently via the recruitment of 
pathogenic T-cell specificities [59]. 
Our mucosae are continuously bombarded by foreign antigens in the air that 
we breathe and the food that we eat and yet diseases such as asthma and G-I 
intolerances are relatively rare. This is because our mucosal immune system is 
specifically designed to down-regulate immune responses to such substances. This 
phenomenon can be exploited to induce tolerance to autoantigens, so-called mucosal 
tolerance induction. In terms of tolerogenic therapies this is likely to represent one of 
the safest approaches, potentially applicable to very early disease or even pre-clinical 
disease. The intranasal route appears to be the most potent for mucosal tolerance 
induction but a recent phase 2 RCT of intranasal recombinant Human Cartilage 
glycoprotein-39 (HCGP-39), a potential RA autoantigen, failed to demonstrate benefit 
after 13 weeks [60].  There are a number of potential explanations for this result, 
relating to trial design and other factors, including the possibility that HCGP-39 is not 
an autoantigen in RA. Again, the lack of tolerance biomarkers severely restricts 
interpretation of these data. In contrast, a recent phase I/II study in T1D employed a 
plasmid that encodes pro-insulin. Details of the trial, including route of 
administration, are limited but therapy is reported to have stabilised C-peptide and 
reduced glycosylated haemoglobin levels [61]. 
The lessons to be learned from atopy are that, if we can identify a robust 
autoantigen, interventions based around this antigen may have powerful effects, with 
the added advantage of providing useful surrogate markers of efficacy and potential 
biomarkers of tolerance induction. Unfortunately T-cell autoantigens have thus far 
proved elusive and inconsistent in RA, and the few clinical trials that have taken place 
have provided negative results. However, the potential rewards of antigen-specific 
therapy are great, in particular the possibility of applying mucosal tolerance 
approaches (which should be very safe) in early or pre-clinical disease. 
  
5. Juvenile Idiopathic Arthritis (JIA) 
Tolerance is an active process and therefore attempts to induce therapeutic 
tolerance will require a minimum level of immune functionality. For example, a 
functioning thymus is needed to generate a new T-cell repertoire following depleting 
therapies, and effective regulatory T-cell function appears essential for robust and 
lasting tolerance induction. Autologous stem cell transplantation (ASCT) as a 
treatment for autoimmunity involves aggressive lymphocyte depletion using drugs 
such as cyclophosphamide and anti-lymphocyte antibodies followed by the infusion 
of T-cell depleted autologous stem cells, harvested from the patient’s peripheral blood 
at an earlier timepoint. The rationale behind this relatively aggressive approach is to 
enable a new, non-autoreactive, immune system, to fill the space vacated by the 
eradicated, diseased one. There are several caveats to this approach: conditioning is 
unlikely to eradicate every autoreactive lymphocyte; similarly the stem cell ‘graft’ 
may contain autoreactive cells; and the graft clearly carries genes that predispose to 
autoimmunity, so disease could recur. Earlier discussions around delayed 
reconstitution, and immune homeostasis, are also clearly relevant in this setting. 
Indeed, in RA patients ASCT was associated with a period of symptomatic 
improvement, not dissimilar to that previously achieved with alemtuzumab [62]. In 
contrast, long-term disease remissions have been noted in other conditions such as 
SLE, MS and, notably, JIA. In JIA therapy was followed by the appearance of 
regulatory T-cells, at least some of which appeared to be newly generated in the 
thymus. The regenerating immune system also exhibited a less inflammatory cytokine 
profile [63, 64]. Similarly, in SLE and MS long term remissions have followed 
ASCT, in association with profound changes in the TCR repertoire and other evidence 
of immune regulation such as emergence of FoxP3+ T-cells, and normalisation of 
dysregulated B-cell homeostasis [65, 66]. These data suggest that an autoreactive 
immune system may not need to be completely eradicated and replaced to achieve 
long-term disease remission. Provided there is a degree of immune ‘plasticity’, 
immunomodulatory therapy may provide an environment or ‘space’ to enable 
dominant tolerance mechanisms to re-emerge and suppress any residual disease-
related clones. In other words, the targetted immune system strives to regain its 
natural state of self-tolerance. This is an exciting concept because it does not rely on 
the rheumatologist or immunotherapist to understand and target every facet of the 
autoimmune diathesis. On the other hand it also suggests that the lack of plasticity 
may render tolerance harder to induce. For example, the sub-optimal response to 
ASCT in RA could reflect the existence of protective microenvironments or niches in 
the inflamed synovium for autoreactive clones [67]. Similarly, the immune system in 
RA patients displays a number of features that could limit its plasticity. These include 
suppressed thymic function, an ‘exhausted’ lymphocyte phenotype and a dysregulated 
cytokine environment that may affect immune homeostasis [68, 69]. Regulatory T-
cells are also dysfunctional in RA, and B cell tolerance check points may also be 
defective [70, 71]. Therefore, whilst attempts to induce therapeutic tolerance in RA 
must continue, this could be a disease where engraftment of an allogeneic immune 
system, perhaps combined with thymic ‘adjuvants’ may provide the best chance of 
success [72, 73].  
In summary, ASCT in JIA has confirmed that our immune systems are 
intrinsically programmed to avoid autoreactivity, and appropriate therapy may 
provide an opportunity for endogenous tolerance mechanisms to re-establish 
themselves (Figure 2). On the other hand this renders it important to understand the 
immune defects present in diseases such as RA, and to target these as part of our 
tolerogenic regime. 
 
6. Graft versus host disease and cellular therapies 
As a potential alternative to haematopoietic transplantation, it may soon be possible to 
specifically target and replace malfunctioning cell types and subsets. Several groups 
are developing methods for expanding and reinfusing autologous Tregs, although 
these may need to be antigen-specific to fully harness their potential [74, 75]. An 
alternative approach may be to encourage the conversion of non-regulatory peripheral 
blood T-cell subsets to Tregs [76]. Tolerogenic dendritic cells (tolDC) are another cell 
type that could be used to instruct the development of a tolerant immune system, and 
plans are underway for a proof-of concept trial in RA [77]. As bespoke therapies, both 
of these will be expensive to produce and available only in specialised centres that 
contain Good Manufacturing Process (GMP) laboratories and the technical expertise 
to reliably generate these sophisticated products. Consequently such therapies may 
first enter the clinic to treat haematological conditions such as graft versus host 
disease (GvHD). The success of such strategies in rheumatic disease additionally 
requires the appropriate cell types to function normally under disease-associated 
conditions, which is not necessarily the case for Tregs in RA [70]. On the other hand 
mesenchymal stem cells (or mesenchymal stromal cells, MSC) could provide an off-
the-shelf therapy capable of restoring tolerance. Derived from various sources, 
including bone marrow and adipose tissue, these cells display lineage markers 
suggestive of a stromal origin [78]. They are pluripotential, capable of giving rise to 
fat, cartilage, bone, muscle and other tissues when cultured under appropriate 
conditions. However, they are also potently immunosuppressive and potentially 
tolerogenic. Following activation they produce indole amine dioxygenase (IDO), an 
enzyme that converts tryptophan to kynurenine, thereby inhibiting T-cell proliferation 
[79]. MSC appear to have multiple properties that could benefit established 
autoimmunity, including T-cell modulation and Treg induction [80]. Furthermore, 
their propensity to home to sites of inflammation and tissue damage could focus their 
activities, including a reparative potential, at appropriate sites [81]. MSC have already 
been applied to the management of severe, steroid-refractory graft versus host disease, 
with preliminary evidence of success [82]. Because they act in a non-MHC restricted 
fashion and are not themselves immunogenic, they can essentially be used ‘off the 
shelf’, potentially providing a therapy for a number of applications, extending from 
the management of autoimmunity to tissue engineering [82].  
In summary, rheumatologists and haematologists have collaborated for many years in 
the context of ASCT for refractory autoimmune disease. This liaison is likely to 
strengthen as different cellular therapies approach clinical application. In terms of 
autoimmunity, MSC are likely to compete with tolDC to provide the first ‘proof of 
concept’ of a cellular therapy. However, many questions will need to be addressed, 
including cell dosage, route of administration, and antigen specificity, as well as 
optimal background therapies. 
 
Current RA management and applying these lessons to trial design 
Previous attempts to induce therapeutic tolerance in RA have been unsuccessful. 
However our general approach to therapy has changed since trials of ant-CD4 and 
similar mAbs were conducted. We now treat disease earlier, with more aggressive 
drug regimes, even starting to treat patients with early inflammatory arthritis but no 
firm label of RA [83, 84]. The immune dysregulation of established RA may mitigate 
against attempts at tolerance induction but, in early RA, even conventional drugs have 
lasting influences on disease progression, the so-called ‘window of opportunity’. 
Therefore our best hopes for tolerance induction must be in early intervention trials 
and, whilst not futile, trials in established disease have a higher hurdle to jump. Trial 
design should also incorporate step-down regimes whereby the potentially tolerogenic 
drug is ultimately withdrawn, which is also aligned with some current practice. 
Interestingly, a small study of short-term infliximab use in newly diagnosed RA 
demonstrated that the drug could be withdrawn in many patients with maintained 
disease remission, although methotrexate was continued [85]. Infliximab would not 
generally be considered a tolerogenic drug but can boost regulatory T-cell function so 
we now need larger studies of similar design, incorporating drugs such as non-
activating anti-CD3 [70, 86]. Withdrawal design studies in which all participants 
initially receive active drug, followed by withdrawal in one group, should be an 
ethically acceptable way to test tolerogenic drugs. The question of ‘bridging’ therapy 
during the period of tolerance induction remains to be addressed. Would steroids be a 
suitable therapy or would they interfere with tolerance mechanisms? Alternatively, 
perhaps infliximab could safely suppress inflammation during that brief window? 
These are exciting times and it seems that current practice is moving towards a trial 
design that will enable us to robustly test the concept of therapeutic tolerance 
induction in inflammatory arthritis. 
 
Summary 
Over recent years, therapeutic tolerance has graduated from a pre-clinical concept to a 
clinical reality, at least in transplantation. Promising data are also emerging in atopy, 
where antigen-specific approaches are providing robust evidence for immune 
modulation. In autoimmunity, non-antigen-specific therapy looks promising in T1D 
and MS. In this chapter we have tried to summarise some of the salient lessons for RA 
that are emerging from work in these other conditions (Figure 3). Perhaps the most 
important is the need for robust biomarkers of tolerance induction, with which to 
guide therapy. However we have also learnt, optimistically, that therapeutic tolerance 
is not an ‘all or none’ phenomenon. The natural state of our immune system is one of 
self-tolerance and if drugs can provide a ‘nudge’ in the right direction and the 
diseased immune system retains sufficient residual plasticity, the task can be finished 
by the re-emergence of endogenous tolerance mechanisms, as seen following ASCT 
in JIA, SLE and MS. Finally, it is reassuring that our current approaches to RA 
management could be readily adapted to robust trials of tolerogenic drugs. 
 
 
Practice Points 
• Tolerance occurs ‘naturally’ in some transplant recipients, and can also be 
induced by creating ‘mixed chimeras’ with non-myeloablative 
haematopoietic transplantation. 
• Long-term remission is achievable with autologous stem cell transplantation 
in JIA, SLE, and MS. 
• Long-term remission has also been achieved in T1D and MS using non-
depleting and depleting anti-T-cell mAbs respectively 
• Peptide therapy can very specifically modulate the dysregulated immune 
response in atopic conditions. 
• In general, tolerance induction should be easier to achieve in early disease. 
 
Research Agenda 
• Robust biomarkers are required to identify the truly tolerant patient and to 
help to design tolerance trials 
• A better understanding is required of the effects of conventional anti-
inflammatory and immunosuppressive drugs on tolerance induction 
• We need a better understanding of immune function and dysfunction in RA, 
including a better definition of autoreactivity and identification of 
autoantigens. 
 
Figure legends 
Figure 1. Tolerance in autoimmunity and transplantation. Tolerance is readily 
recognisable in transplantation (left), when a recipient retains a foreign organ 
graft without the need for immunosuppression.  The situation is less clear in 
autoimmune disease (right hand panel).  Even when a patient is in remission on 
no therapy this could represent the natural pattern of disease with relapses and 
remissions.  Biomarkers of tolerance are needed to distinguish these scenarios. 
 
Figure 2. In the tolerant state, potential autoreactivity is balanced by 
immunoregulatory mechanisms (top panel). This balance becomes disturbed in 
immunopathology (middle panel). Tolerogenic therapy re-establishes a new 
balance. Because this is an active process the new set state may not be absolutely 
identical to the naturally tolerant state (bottom panel). 
 
Figure 3. Lessons learned. This figure recapitulates the lessons highlighted in the 
main article. 
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